A Change In Stance Filament Health Corp (FH.NE) announced today that Psilo Scientific Ltd., the Company’s wholly-owned subsidiary, has joined Health Canada’s list of licensed psilocybin producers. No, we…
Filament
$41.189M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has received approval from Health Canada for a Phase 2 clinical trial utilizing the Company’s standardized natural psilocybin…
Filament Health Corp. (FH.NE) (“Filament”) announced today that it will be participating in three conferences throughout December 2021. These conferences include the Horizons: Perspectives on Psychedelics Conference, H.C. Wainwright 2nd…
Filament Health Corp. (FH.NE) announced today that it has entered into a co-development and exclusive licensing agreement with EntheoTech Bioscience Inc. “Our partnership with EntheoTech showcases our commitment to…
Filament Health Corp. (FH.NEO) announced today that the Company has received FDA authorization to initiate the first clinical trial using naturally-sourced psychedelic substances. Additionally, this is the first approval…
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been…
For the vast majority of the history of human use of psychedelics, they have been seen as something sacred, a gift from God or mother nature herself. Ayahuasca, which…